Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PEN

Penumbra Inc

Oct 31 • 09:32AM ET

228.95

-2.59 -1.12 %

Healthcare • Medical Devices • USA • NYSE

Peers: BSX ISRG EW HOLX MDT JNJ ABT SYK ZBH TFX

| Held by: VTI IJH VB VBK VXF XMHQ MDY IWP XMMO IHI

Scroll to Statements

Index	-	P/E	60.71	EPS (ttm)	3.77	Insider Own	3.17%	Shs Outstand	38.97M	Perf Week	-9.50%
Market Cap	8.93B	Forward P/E	45.57	EPS next Y	5.02	Insider Trans	-12.84%	Shs Float	37.76M	Perf Month	-9.68%
Enterprise Value	8.72B	PEG	1.45	EPS next Q	0.93	Inst Own	92.25%	Short Float	4.59%	Perf Quarter	-4.76%
Income	147.70M	P/S	6.97	EPS this Y	69.13%	Inst Trans	2.95%	Short Ratio	4.13	Perf Half Y	-22.65%
Sales	1.28B	P/B	6.90	EPS next Y	33.81%	ROA	9.20%	Short Interest	1.73M	Perf YTD	-3.59%
Book/sh	33.20	P/C	21.03	EPS next 5Y	41.74%	ROE	12.03%	52W High	310.00 -26.15%	Perf Year	9.22%
Cash/sh	10.89	P/FCF	55.25	EPS past 3/5Y	36.76% -23.21%	ROIC	9.85%	52W Low	207.58 10.29%	Perf 3Y	29.48%
Dividend Est.	-	EV/EBITDA	47.96	Sales past 3/5Y	16.91% 16.89%	Gross Margin	66.44%	Volatility	4.56% 3.25%	Perf 5Y	-3.28%
Dividend TTM	-	EV/Sales	6.82	EPS Y/Y TTM	918.46%	Oper. Margin	12.45%	ATR (14)	7.92	Perf 10Y	500.13%
Dividend Ex-Date	-	Quick Ratio	4.04	Sales Y/Y TTM	12.92%	Profit Margin	11.54%	RSI (14)	27.96	Recom	1.48
Dividend Gr. 3/5Y	- -	Current Ratio	6.75	EPS Q/Q	174.33%	SMA20	-8.08%	Beta	0.52	Target Price	310.56
Payout	0.00%	Debt/Eq	0.17	Sales Q/Q	13.38%	SMA50	-11.30%	Rel Volume	0.17	Prev Close	231.54
Employees	4500	LT Debt/Eq	0.16	Earnings	Nov 05 AMC	SMA200	-13.19%	Avg Volume	420.21K	Price	228.95
IPO	Sep 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.27% 3.57%	Trades		Volume	3,817	Change	-1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-08-25	Upgrade	Needham	Hold → Buy	$326
Sep-02-25	Initiated	Evercore ISI	Outperform	$300
Mar-14-25	Initiated	BofA Securities	Buy	$320
Jan-21-25	Initiated	UBS	Buy	$305
Dec-17-24	Initiated	Oppenheimer	Outperform	$275
Dec-11-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$190 → $275
Sep-18-24	Initiated	Stifel	Buy	$238
Sep-03-24	Initiated	Leerink Partners	Outperform	$263
Jul-31-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$289 → $150
Jul-31-24	Downgrade	Citigroup	Buy → Neutral	$165 → $178
Feb-23-24	Downgrade	JP Morgan	Overweight → Neutral	$284 → $250
Sep-06-23	Initiated	Morgan Stanley	Equal-Weight	$265
Jul-19-23	Initiated	Robert W. Baird	Outperform	$375
Mar-29-23	Downgrade	Needham	Buy → Hold
Jan-30-23	Initiated	Piper Sandler	Overweight	$275
Nov-04-22	Upgrade	Citigroup	Neutral → Buy	$217 → $212
Oct-12-22	Initiated	Jefferies	Buy	$230
Oct-05-22	Downgrade	Citigroup	Buy → Neutral	$170 → $217
Sep-09-22	Upgrade	Needham	Hold → Buy
Jul-18-22	Initiated	RBC Capital Mkts	Outperform	$195

Show Previous Ratings

Oct-28-25 03:20PM	Why Penumbra (PEN) Shares Are Falling Today (StockStory) -5.04%
Oct-27-25 09:00AM	Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism (PR Newswire)
Oct-26-25 05:00PM	Can Penumbra's 'Landmark' Study Vs. Blood Thinners Change Guidelines? (Investor's Business Daily)
Oct-20-25 06:31AM	Needham Upgrades Penumbra (PEN) to Buy Amid 2026 Growth Outlook (Insider Monkey)
Oct-13-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
04:30PM	Loading…
Oct-08-25 04:30PM	Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025 (PR Newswire)
11:35AM	Penumbra (PEN) Stock Trades Up, Here Is Why (StockStory)
09:45AM	Intel, FedEx downgraded: Wall Street's top analyst calls (The Fly)
Oct-01-25 01:58PM	Penumbra, Inc. (PEN) Promotes Shruthi Narayan to President to Drive Global Growth (Insider Monkey)
Sep-24-25 11:40AM	TFX vs. PEN: Which Stock Should Value Investors Buy Now? (Zacks)
Sep-18-25 08:48AM	What Makes Penumbra (PEN) a Good Investment? (Insider Monkey)
Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Sep-09-25 09:00AM	New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile (PR Newswire)
Sep-06-25 10:44PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Sep-02-25 09:45AM	Elf Beauty downgraded, Zscaler upgraded: Wall Street's top analyst calls (The Fly)
11:30AM	Loading…
Aug-29-25 11:30AM	Why Is TransMedics (TMDX) Down 1.9% Since Last Earnings Report? (Zacks)
Aug-28-25 11:30AM	Why Is Penumbra (PEN) Up 5% Since Last Earnings Report? (Zacks)
Aug-27-25 11:34PM	Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2 (StockStory)
09:00AM	Penumbra, Inc. Names Shruthi Narayan as Company President (PR Newswire)
Aug-22-25 12:01AM	Penumbra (PEN): Buy, Sell, or Hold Post Q2 Earnings? (StockStory) +5.32%
Aug-20-25 04:30PM	Penumbra, Inc. to Present at Upcoming Investor Conferences (PR Newswire)
Aug-19-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Aug-13-25 05:50PM	Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know (StockStory)
Aug-12-25 12:52AM	PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance (StockStory)
12:42AM	5 Insightful Analyst Questions From Penumbra's Q2 Earnings Call (StockStory)
Jul-31-25 08:59AM	Should You Invest in Penumbra (PEN)? (Insider Monkey)
Jul-30-25 04:30PM	Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire) +11.91%
01:40PM	Penumbra (PEN) Shares Skyrocket, What You Need To Know (StockStory)
03:16AM	Penumbra Inc (PEN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Jul-29-25 05:30PM	Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:27PM	Loading…
05:27PM	Penumbra's (NYSE:PEN) Q2: Strong Sales, Stock Soars (StockStory)
05:20PM	Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:18PM	Penumbra: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports Second Quarter 2025 Financial Results (PR Newswire)
11:40AM	ITGR vs. PEN: Which Stock Is the Better Value Option? (Zacks)
Jul-27-25 11:08PM	Penumbra (PEN) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-24-25 12:10PM	Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
10:00AM	Mettler-Toledo (MTD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-22-25 10:00AM	Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-11-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
Jul-10-25 12:39AM	Penumbra (PEN) Announces Completion of Enrollment in STORM-PE Clinical Trial (Insider Monkey)
Jul-01-25 04:30PM	Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025 (PR Newswire)
Jun-25-25 11:40AM	ITGR vs. PEN: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 01:18PM	Penumbra may gain market share in peripheral embolisation coils with Ruby XL (Medical Device Network)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:27AM	The Top 5 Analyst Questions From Penumbra's Q1 Earnings Call (StockStory)
Jun-18-25 11:33PM	Winners And Losers Of Q1: Penumbra (NYSE:PEN) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks (StockStory)
Jun-17-25 09:46AM	Penumbra completes enrolment in trial for pulmonary embolism (Medical Device Network)
Jun-16-25 09:00AM	Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial (PR Newswire)
Jun-13-25 06:20AM	Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? (Zacks)
Jun-09-25 11:40AM	ITGR or PEN: Which Is the Better Value Stock Right Now? (Zacks)
11:35AM	Zacks Industry Outlook Penumbra, Integer and AngioDynamics (Zacks)
08:37AM	PEN Stock Rises Following the Launch of Ruby XL System (Zacks)
Jun-06-25 09:41AM	3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom (Zacks)
05:15AM	Penumbra announces FDA clearance and launch of detachable embolisation coil (Medical Device Network)
Jun-05-25 09:00AM	Penumbra Introduces the Ruby XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization (PR Newswire)
06:20AM	Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? (Zacks)
Jun-03-25 12:02AM	3 Reasons to Sell PEN and 1 Stock to Buy Instead (StockStory)
May-30-25 09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
May-23-25 11:30AM	Why Is Penumbra (PEN) Down 10.6% Since Last Earnings Report? (Zacks)
May-22-25 06:46AM	Penumbra Rallies 35.9% in a Year: What's Driving the Stock? (Zacks)
May-20-25 04:30PM	Penumbra, Inc. to Present at Upcoming Investor Conferences (PR Newswire)
12:38AM	3 Healthcare Stocks Walking a Fine Line (StockStory)
May-15-25 09:50AM	Here's Why Penumbra (PEN) is a Strong Momentum Stock (Zacks)
May-14-25 09:45AM	Here's Why Penumbra (PEN) is a Strong Growth Stock (Zacks)
May-09-25 01:09PM	Why IBD Stock Of The Day Penumbra, Up 27% This Year, Is Making A Comeback (Investor's Business Daily)
10:23AM	Should You Consider Adding Penumbra (PEN) To Your Portfolio? (Insider Monkey)
May-07-25 04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 12:50PM	3 Mid-Cap Medical Stocks Outperforming the Market (MarketBeat)
May-03-25 08:00AM	Spotify Breaks Out After Apple Ruling, Leads 5 Stocks Near Buy Points (Investor's Business Daily)
May-01-25 11:35AM	ClearBridge Small Cap Growth Fund Q1 2025 Commentary (Seeking Alpha)
12:37AM	3 Profitable Stocks in the Doghouse (StockStory)
Apr-29-25 04:30PM	Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference (PR Newswire)
11:45AM	Baron Health Care Fund Q1 2025 Top Net Purchases And Sales (Seeking Alpha)
09:50AM	Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term (Zacks)
03:10AM	Bausch + Lomb (BLCO) Reports Q1: Everything You Need To Know Ahead Of Earnings (StockStory)
03:09AM	GE HealthCare (GEHC) Reports Q1: Everything You Need To Know Ahead Of Earnings (StockStory)
03:09AM	Align Technology Earnings: What To Look For From ALGN (StockStory)
03:05AM	What To Expect From CONMED's (CNMD) Q1 Earnings (StockStory)
Apr-28-25 12:45PM	3 Reasons Growth Investors Will Love Penumbra (PEN) (Zacks)
09:45AM	Why Penumbra (PEN) is a Top Growth Stock for the Long-Term (Zacks)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-24-25 10:42AM	Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand (Zacks) +6.99%
08:10AM	Q1 2025 Penumbra Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Penumbra Inc (PEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst International ... (GuruFocus.com)
Apr-23-25 08:15PM	Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:32PM	Penumbra's (NYSE:PEN) Q1 Sales Beat Estimates, Stock Soars (StockStory)
05:15PM	Penumbra (PEN) Q1 Earnings and Revenues Top Estimates (Zacks)
04:17PM	Penumbra: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Penumbra, Inc. Reports First Quarter 2025 Financial Results (PR Newswire)
Apr-22-25 01:04PM	Stroke Management Drug Firm Climbs To Key Level Ahead Of Earnings; But Beware This Pharma Tariff (Investor's Business Daily)
08:04AM	What To Expect From Penumbra's (PEN) Q1 Earnings (StockStory)
Apr-21-25 12:10PM	Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again (Zacks)
Apr-17-25 10:01AM	Integer (ITGR) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-16-25 10:00AM	Penumbra (PEN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-10-25 08:46AM	Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last? (Zacks)
Apr-09-25 05:13AM	3 Reasons PEN is Risky and 1 Stock to Buy Instead (StockStory) +7.68%
Apr-08-25 09:57AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Apr-03-25 04:30PM	Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 (PR Newswire)

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grewal Harpreet	Director	Oct 02 '25	Sale	248.61	186	46,241	8,702	Oct 03 07:32 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Oct 01 '25	Sale	249.70	600	149,820	64,257	Oct 03 07:31 PM
Wilder Thomas	Director	Oct 01 '25	Sale	253.93	186	47,231	186	Oct 03 07:30 PM
Grewal Harpreet	Director	Oct 02 '25	Proposed Sale	248.61	186	46,241		Oct 02 04:03 PM
Johanna Roberts	Officer	Oct 01 '25	Proposed Sale	253.22	1,800	455,796		Oct 01 04:08 PM
THOMAS WILDER	Director	Oct 01 '25	Proposed Sale	253.93	186	47,231		Oct 01 04:01 PM
Grewal Harpreet	Director	Sep 02 '25	Sale	272.19	186	50,627	8,888	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Option Exercise	30.00	27,980	839,400	198,260	Sep 04 07:36 PM
Elsesser Adam	CEO	Sep 03 '25	Sale	269.65	15,800	4,260,457	182,460	Sep 04 07:36 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Sep 02 '25	Sale	270.58	600	162,347	64,857	Sep 04 07:36 PM
ADAM ELSESSER	Officer	Sep 03 '25	Proposed Sale	269.65	15,800	4,260,404		Sep 03 04:51 PM
Grewal Harpreet	Director	Sep 02 '25	Proposed Sale	272.19	186	50,627		Sep 02 03:59 PM
Elsesser Adam	CEO and President	Aug 20 '25	Option Exercise	30.00	27,976	839,280	186,180	Aug 22 07:48 PM
Elsesser Adam	CEO and President	Aug 20 '25	Sale	254.53	15,900	4,046,952	170,280	Aug 22 07:48 PM
ADAM ELSESSER	Officer	Aug 20 '25	Proposed Sale	254.53	15,900	4,046,989		Aug 20 04:28 PM
Yuen Maggie	Chief Financial Officer	Aug 15 '25	Option Exercise	158.30	724	114,609	13,667	Aug 15 07:49 PM
Yuen Maggie	Chief Financial Officer	Aug 13 '25	Sale	250.00	2,000	500,000	12,943	Aug 15 07:49 PM
Bose Arani	Director	Aug 13 '25	Sale	250.65	12,000	3,007,776	558	Aug 15 07:44 PM
Wilder Thomas	Director	Aug 12 '25	Sale	240.16	372	89,340	372	Aug 13 07:44 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Aug 11 '25	Sale	238.94	600	143,363	65,457	Aug 13 07:40 PM
Arani Bose	Affiliate	Aug 13 '25	Proposed Sale	248.55	12,000	2,982,600		Aug 13 05:24 PM
MAGGIE YUEN	Officer	Aug 13 '25	Proposed Sale	250.00	2,000	500,000		Aug 13 04:04 PM
THOMAS WILDER III	Director	Aug 12 '25	Proposed Sale	240.16	372	89,340		Aug 12 04:05 PM
Elsesser Adam	CEO and President	Aug 06 '25	Option Exercise	30.00	27,976	839,280	174,234	Aug 08 08:06 PM
Elsesser Adam	CEO and President	Aug 06 '25	Sale	238.20	16,030	3,818,363	158,204	Aug 08 08:06 PM
ADAM ELSESSER	Officer	Aug 06 '25	Proposed Sale	238.20	16,030	3,818,397		Aug 06 04:48 PM
Elsesser Adam	CEO and President	Jul 23 '25	Option Exercise	30.00	27,976	839,280	162,408	Jul 25 07:32 PM
Elsesser Adam	CEO and President	Jul 23 '25	Sale	233.16	16,150	3,765,574	146,258	Jul 25 07:32 PM
ADAM ELSESSER	Officer	Jul 23 '25	Proposed Sale	233.16	16,150	3,765,610		Jul 23 04:15 PM
Elsesser Adam	CEO and President	Jul 09 '25	Option Exercise	30.00	27,976	839,280	150,417	Jul 11 07:30 PM
Elsesser Adam	CEO and President	Jul 09 '25	Sale	243.75	15,985	3,896,344	134,432	Jul 11 07:30 PM
ADAM ELSESSER	Officer	Jul 09 '25	Proposed Sale	243.75	15,985	3,896,329		Jul 09 04:27 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jul 01 '25	Sale	252.70	600	151,622	66,057	Jul 03 07:54 PM
Johanna Roberts	Officer	Jul 01 '25	Proposed Sale	256.63	3,000	769,890		Jul 01 04:51 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 25 '25	Option Exercise	22.04	1,943	42,824	66,657	Jun 27 08:04 PM
Elsesser Adam	CEO and President	Jun 25 '25	Option Exercise	30.00	27,976	839,280	138,331	Jun 27 08:02 PM
Elsesser Adam	CEO and President	Jun 25 '25	Sale	253.40	15,890	4,026,589	122,441	Jun 27 08:02 PM
ADAM ELSESSER	Officer	Jun 25 '25	Proposed Sale	253.40	15,890	4,026,585		Jun 25 04:25 PM
O'Rourke Bridget	Director	Jun 16 '25	Sale	259.78	50	12,989	5,373	Jun 18 07:46 PM
BRIDGET A O'ROURKE	Director	Jun 16 '25	Proposed Sale	259.78	50	12,989		Jun 16 04:05 PM
Elsesser Adam	CEO and President	Jun 11 '25	Option Exercise	30.00	27,976	839,280	126,265	Jun 13 07:33 PM
Elsesser Adam	CEO and President	Jun 11 '25	Sale	253.67	15,910	4,035,890	110,355	Jun 13 07:33 PM
ADAM ELSESSER	Officer	Jun 11 '25	Proposed Sale	253.67	15,910	4,035,902		Jun 11 05:09 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Jun 02 '25	Sale	258.17	600	154,903	64,714	Jun 04 07:30 PM
Elsesser Adam	CEO and President	May 28 '25	Option Exercise	30.00	27,976	839,280	114,589	May 30 08:02 PM
Elsesser Adam	CEO and President	May 28 '25	Sale	267.91	16,300	4,366,920	98,289	May 30 08:02 PM
ADAM ELSESSER	Officer	May 28 '25	Proposed Sale	267.91	16,300	4,366,915		May 28 04:08 PM
Elsesser Adam	CEO and President	May 14 '25	Option Exercise	30.00	27,976	839,280	103,213	May 16 07:35 PM
Elsesser Adam	CEO and President	May 14 '25	Sale	298.22	16,600	4,950,476	86,613	May 16 07:35 PM
O'Rourke Bridget	Director	May 15 '25	Sale	286.15	100	28,615	5,423	May 16 07:33 PM
BRIDGET A O'ROURKE	Director	May 15 '25	Proposed Sale	286.15	100	28,615		May 15 04:03 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 12 '25	Option Exercise	22.04	55	1,212	66,214	May 14 07:53 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	May 12 '25	Sale	298.55	900	268,698	65,314	May 14 07:53 PM
ADAM ELSESSER	Officer	May 14 '25	Proposed Sale	298.22	16,600	4,950,469		May 14 04:22 PM
Elsesser Adam	CEO and President	May 07 '25	Option Exercise	30.00	27,976	839,280	91,887	May 09 07:35 PM
Elsesser Adam	CEO and President	May 07 '25	Sale	289.37	16,650	4,818,006	75,237	May 09 07:35 PM
ADAM ELSESSER	Officer	May 07 '25	Proposed Sale	289.35	16,650	4,817,704		May 07 04:44 PM
Yuen Maggie	Chief Financial Officer	May 06 '25	Option Exercise	158.30	900	142,470	14,857	May 06 07:30 PM
Yuen Maggie	Chief Financial Officer	May 02 '25	Sale	299.01	2,000	598,020	13,957	May 06 07:30 PM
MAGGIE YUEN	Officer	May 02 '25	Proposed Sale	299.01	2,000	598,020		May 02 04:06 PM
Bose Arani	Director	Apr 25 '25	Sale	298.73	12,000	3,584,775	302,819	Apr 29 07:34 PM
Kassing Don W.	Director	Apr 29 '25	Proposed Sale	277.35	8,500	2,357,475		Apr 29 05:32 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Option Exercise	22.04	600	13,224	66,759	Apr 25 07:55 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 24 '25	Sale	300.01	600	180,006	66,159	Apr 25 07:55 PM
Elsesser Adam	CEO and President	Apr 16 '25	Option Exercise	30.00	27,976	839,280	80,471	Apr 18 07:38 PM
Elsesser Adam	CEO and President	Apr 16 '25	Sale	274.35	16,560	4,543,228	63,911	Apr 18 07:38 PM
O'Rourke Bridget	Director	Apr 15 '25	Sale	271.21	50	13,560	5,523	Apr 17 07:34 PM
ADAM ELSESSER	Officer	Apr 16 '25	Proposed Sale	274.35	16,560	4,543,181		Apr 16 04:41 PM
Elsesser Adam	CEO and President	Apr 02 '25	Option Exercise	30.00	41,308	1,239,240	69,060	Apr 04 08:38 PM
Elsesser Adam	CEO and President	Apr 02 '25	Sale	272.24	16,565	4,509,728	52,495	Apr 04 08:38 PM
Wilder Thomas	Director	Apr 02 '25	Sale	266.93	360	96,095	4,692	Apr 04 08:36 PM
Wilder Thomas	Director	Mar 31 '25	Sale	264.58	360	95,249	4,533	Apr 02 07:34 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Option Exercise	22.04	600	13,224	66,953	Apr 02 07:33 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Apr 01 '25	Sale	269.11	600	161,466	66,353	Apr 02 07:33 PM
Grewal Harpreet	Director	Apr 01 '25	Sale	267.17	200	53,434	9,074	Apr 02 07:33 PM
THOMAS AND CATHARINE WILDER FA	Director	Apr 02 '25	Proposed Sale	266.93	360	96,095		Apr 02 04:04 PM
ADAM ELSESSER	Officer	Apr 02 '25	Proposed Sale	272.24	16,565	4,509,702		Apr 02 04:02 PM
Grewal Harpreet	Director	Apr 01 '25	Proposed Sale	267.17	200	53,434		Apr 01 04:07 PM
DON W KASSING	Director	Apr 01 '25	Proposed Sale	267.17	166	44,350		Apr 01 04:06 PM
THOMAS AND CATHARINE WILDER FA	Director	Mar 31 '25	Proposed Sale	264.58	360	95,249		Mar 31 04:03 PM
Bose Arani	Director	Mar 25 '25	Sale	283.77	12,000	3,405,253	314,819	Mar 27 08:01 PM
Elsesser Adam	CEO and President	Mar 19 '25	Option Exercise	30.00	27,976	839,280	44,352	Mar 21 07:32 PM
Elsesser Adam	CEO and President	Mar 19 '25	Sale	276.21	16,600	4,585,138	27,752	Mar 21 07:32 PM
ADAM ELSESSER	Officer	Mar 19 '25	Proposed Sale	276.21	16,600	4,585,104		Mar 19 04:27 PM
Elsesser Adam	CEO and President	Mar 05 '25	Option Exercise	30.00	72,976	2,189,280	77,976	Mar 07 08:03 PM
Elsesser Adam	CEO and President	Mar 05 '25	Sale	283.59	61,600	17,468,917	16,376	Mar 07 08:03 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Option Exercise	22.04	600	13,224	67,139	Mar 05 07:37 PM
Roberts Johanna	EVP, Gen. Counsel & Secretary	Mar 03 '25	Sale	287.43	600	172,458	66,539	Mar 05 07:37 PM
O'Rourke Bridget	Director	Mar 03 '25	Sale	285.48	50	14,274	5,573	Mar 05 07:36 PM
Bose Arani	Director	Mar 03 '25	Sale	287.42	12,000	3,448,993	326,819	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 05 '25	Option Exercise	158.30	900	142,470	16,143	Mar 05 07:35 PM
Yuen Maggie	Chief Financial Officer	Mar 03 '25	Sale	286.00	2,000	571,995	15,243	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Option Exercise	22.04	9,200	202,768	33,470	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 03 '25	Sale	285.93	7,288	2,083,860	24,270	Mar 05 07:35 PM
Shiu Lambert	Chief Accounting Officer	Mar 04 '25	Sale	282.88	501	141,723	32,969	Mar 05 07:35 PM
ADAM ELSESSER	Officer	Mar 05 '25	Proposed Sale	283.59	61,600	17,468,975		Mar 05 04:27 PM
LAMBERT SHIU	Officer	Mar 04 '25	Proposed Sale	282.88	501	141,723		Mar 04 05:10 PM
Arani Bose	Affiliate	Mar 03 '25	Proposed Sale	285.44	48,000	13,701,120		Mar 03 04:47 PM
MAGGIE YUEN	Officer	Mar 03 '25	Proposed Sale	286.00	2,000	571,995		Mar 03 04:39 PM
LAMBERT SHIU	Officer	Mar 03 '25	Proposed Sale	285.93	7,288	2,083,853		Mar 03 04:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEN

Penumbra Inc

Upgrade your FINVIZ experience